Inflammatory Bowel Disease CD56+ NK Cells

Inflammatory Bowel Disease CD56+ NK Cells for Mucosal Immunology Research

Inflammatory Bowel Disease (IBD) CD56+ NK Cells are cryopreserved from peripheral blood of IRB-consented adult donors diagnosed with IBD. These CD56+ CD3− natural killer cells reflect disease-associated innate immune alterations and support studies of immune surveillance, inflammation, and cytotoxicity.

NK Cells and Innate Lymphocytes in IBD

IBD is an immune-mediated inflammatory disease driven by a dysregulated mucosal response to intestinal microbiota rather than by autoimmunity against a defined self-antigen. The innate lymphocyte compartment is central to that dysregulation, and NK cells sit within a broader family that behaves in genuinely interesting ways here:

• ILC plasticity — the innate lymphoid cell compartment shifts toward IFN-γ-producing ILC1-like and IL-17-producing ILC3 phenotypes in inflamed intestine, and NK cells overlap phenotypically with ILC1. This plasticity is one of the more active questions in IBD immunology
• Altered cytotoxic capacity and receptor repertoire in circulating NK cells
• Pro-inflammatory cytokine production — IFN-γ and TNF-α contributing to mucosal damage
• Dual role — NK cells appear both to drive inflammation and to help regulate it, depending on subset and context
• Trafficking-directed therapy — vedolizumab blocks α4β7 integrin, altering circulating lymphocyte populations in treated donors

Ulcerative Colitis or Crohn’s Disease?

The two IBD subtypes differ in anatomy, depth of inflammation, and cytokine profile, so subtype-specific cohorts are usually more informative than a mixed set:

• Ulcerative colitis — continuous mucosal inflammation confined to the colon
• Crohn’s disease — patchy transmural inflammation with granulomas, anywhere in the GI tract

Mixed IBD cohorts with per-donor diagnosis annotated are available where the broad category is genuinely what your protocol needs.

Donor Stratification Available

• IBD subtype — UC, Crohn’s, or IBD-unclassified, annotated per donor
• Disease activity — Mayo/UCEIS for UC, HBI/CDAI for Crohn’s, where recorded
• Disease location and extent
• Inflammatory markers — CRP and faecal calprotectin where available
• Treatment status — 5-ASA, thiopurine, anti-TNF, anti-integrin, anti-IL-23, or JAK inhibitor
• Matched healthy controls available

Product Features

• Research Use Only (RUO), CD56+ enriched NK cells
• Isolated from clinically diagnosed IBD donors
• High viability and enrichment
• Cryopreserved in CryoStor® CS10 media
• Processed within 24 hours of collection
• Flow cytometry purity and viability data per lot
• Ethically sourced with IRB approval and HIPAA compliance

De-identified Donor Data

• Confirmed diagnosis of inflammatory bowel disease, including subtype
• Demographics: age, sex assigned at birth, race/ethnicity
• Self-reported clinical history and medication use

Applications

• NK cell phenotype and function studies in IBD
• ILC plasticity and ILC1/ILC3 differentiation research
• Cytotoxicity, degranulation, and CD56-bright/dim subset analysis
• Mucosal immune surveillance studies
• Comparative UC vs Crohn’s studies
• Biologic mechanism-of-action research
• Single-cell analysis and biomarker identification
• Preclinical immunotherapy development

Other IBD Specimen Types

Matched material is available as IBD CD19+ B cells, IBD leukopak, and IBD bulk plasma.

Compliance and Quality Assurance

• IRB-approved collection and 21 CFR Part 11-compliant e-consent
• Standardized processing and quality protocols
• HIPAA-compliant data handling

Ordering & Customization

Inflammatory Bowel Disease CD56+ NK Cells are offered in standard or custom aliquot sizes. For pricing, regulatory documentation, or international support, contact learnmore@sanguinebio.com. For the full range, see our human CD56+ NK cells collection.